- Home
- VNOM vs ALKS Comparison
VNOM vs ALKS Comparison
Compare VNOM & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VNOM | ALKS |
|---|---|---|
| Founded | 2013 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | 2050 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 6.1B |
| IPO Year | 2025 | 2012 |
Fundamental Metrics
Financial Performance| Metric | VNOM | ALKS |
|---|---|---|
| Price | $46.89 | $36.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 14 |
| Target Price | ★ $54.85 | $43.43 |
| AVG Volume (30 Days) | 1.4M | ★ 1.9M |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.87% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | $1,395,000,000.00 | ★ $1,475,899,000.00 |
| Revenue This Year | $69.89 | $24.26 |
| Revenue Next Year | N/A | $4.47 |
| P/E Ratio | $88.45 | ★ N/A |
| Revenue Growth | ★ 62.02 | N/A |
| 52 Week Low | $35.10 | $25.17 |
| 52 Week High | $51.13 | $39.56 |
Technical Indicators
Market Signals| Indicator | VNOM | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 45.31 | 58.04 |
| Support Level | $46.08 | $27.65 |
| Resistance Level | $48.50 | $39.56 |
| Average True Range (ATR) | 1.24 | 1.33 |
| MACD | -0.23 | -0.08 |
| Stochastic Oscillator | 16.04 | 49.36 |
Price Performance
Historical ComparisonAbout VNOM Viper Energy Inc.
Viper Energy Inc is focused on owning and acquiring mineral and royalty interests in oil and natural gas properties in the Permian Basin. The Permian Basin is known to have a number of zones of oil and natural gas-bearing rock throughout.
About ALKS Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.